Abstract
Humans have collected and used hallucinogenic mushrooms for ethnic medicinal, recreational, and religious purposes since before recorded history. Currently, the use of these mushrooms is illegal in most countries, but where their use is legal they are applied as self medication. Psilocybin and psilocin, two psychoactive alkaloids, are naturally synthesized by hallucinogenic mushrooms. The chemical structure of these compounds are similar to the neurotransmitter serotonin. Activation of this system by psilocybin and psilocin may produce temporary changes in the brain that induce hallucinations and feelings of euphoria. Adjustment of the serotonin system in this way can moderate symptoms of related mental disorders. This review summarizes relevant and current information regarding the discovery of hallucinogenic mushrooms and their contained psychoactive compounds, the events that lead to their criminalization and decriminilization, and the state of knowledge of psilocybin, psilocin, and derivatives. Last, research on the psychoactive properties of these mushrooms is placed in perspective to possible applications for human dysfunctions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adachi J, Mizoi Y, Naito T, Yamamoto K, Fujiwara S, Ninomiya I (1991) Determination of beta-carbolines in foodstuffs by high-performance liquid chromatography and high-performance liquid chromatography-mass spectrometry. J Chromatogr 538:331–339
Agurell S, Blomkvist S, Catalfomo P (1966) Biosynthesis of psilocybin in submerged culture of Psilocybe cubensis. 1. Incorporation of labelled tryptophan and tryptamine. Acta Pharm Suec 3:37–44
Agurell S, Nilsson JLG, Liaaen-Jensen S et al (1968) Biosynthesis of psilocybin. Part II. Incorporation of labelled tryptamine derivatives. Acta Chem Scand 22:1210–1218. https://doi.org/10.3891/acta.chem.scand.22-1210
Alam Mahmood Z (2013) Bioactive alkaloids from fungi: Psilocybin. In: Ramawat KG, Merillon JM (eds) Natural products: phytochemistry, botany and metabolism of alkaloids, phenolics and terpenes. Springer-Verlag, Berlin Heidelberg, pp 523–552
Allen JW, Gartz J (2009) Magic mushrooms in some third world countries. Ethnomycological Journals 6, Seattle
Allen JW, Merlin MD, Jansen KLR (1991) An ethnomycological review of psychoactive agarics in Australia and New Zealand. J Psychoactive Drugs 23:39–69. https://doi.org/10.1080/02791072.1991.10472573
Anastos N, Barnett NW, Pfeffer FM, Lewis SW (2006) Investigation into the temporal stability of aqueous standard solutions of psilocin and psilocybin using high performance liquid chromatography. Sci Justice J Forensic Sci Soc 46:91–96. https://doi.org/10.1016/S1355-0306(06)71579-9
Aronson JK (2016a) Meyler’s side effects of drugs: Psilocybin: the international encyclopedia of adverse drug reactions and interactions. pp 1048–1051
Aronson JK (2016b) Meyler’s side effects of drugs: the international encyclopedia of adverse drug reactions and interactions. Meyler’s Side Eff Drugs 48:858–862
Arora D (1986) Mushrooms demystified: a comprehensive guide to the fleshy fungi. Ten Speed Press, California
Awan AR, Winter JM, Turner D, Shaw WM, Suz LM, Bradshaw AJ, Ellis T, Dentinger BT (2018a) Convergent evolution of psilocybin biosynthesis by psychedelic mushrooms. BioRxiv 374199
Awan AR, Winter JM, Turner D et al (2018b) Convergent evolution of psilocybin biosynthesis by psychedelic mushrooms. BioRxiv. https://doi.org/10.1101/374199
Ayipo YO, Yahaya SN, Babamale HF, Ahmad I, Patel H, Mordi MN (2021) ß-Carboline alkaloids induce structural plasticity and inhibition of SARS-CoV-2 nsp3 macrodomain more potently than remdesivir metabolite GS-441524: Computational approach. Turkish J Biol 45:503–517
Barceloux DG (2012) Psilocybin and hallucinogenic mushrooms. Medical toxicology of drug abuse. Wiley, Hoboken, pp 950–960
Baumeister D, Barnes G, Giaroli G, Tracy D (2014) Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles. Ther Adv Psychopharmacol 4:156–169
Belouin SJ, Henningfield JE (2018) Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology 142:7–19
Bogenschutz MP, Forcehimes AA, Pommy JA et al (2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 29:289–299. https://doi.org/10.1177/0269881114565144
Cameron LP, Nazarian A, Olson DE (2020) Psychedelic microdosing: prevalence and subjective effects. J Psychoactive Drugs. https://doi.org/10.1080/02791072.2020.1718250
Carhart-Harris R, Nutt D (2017) Serotonin and brain function: a tale of two receptors. J Psychopharmacol 31:1091–1120. https://doi.org/10.1177/0269881117725915
Carhart-Harris RL, Bolstridge M, Rucker J et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3:619–627. https://doi.org/10.1016/S2215-0366(16)30065-7
Castellanos JP, Woolley C, Bruno KA et al (2020) Chronic pain and psychedelics: a review and proposed mechanism of action. Reg Anesth Pain Med 45:486–494
Chadeayne AR, Golen JA, Manke DR (2019) Bis(4-acetyl-N, N-dimethyltryptammonium) fumarate: a new crystallline form of psilacetin, and alternative to psilocybin as a psilocin prodrug. Crystallogr Commun 75:900–902
Chadeayne AR, Pham DNK, Reid BG, Golen JA, Manke DR (2020) Active metabolite of aeruginascin (4-Hydroxy-N, N, N-trimethyltryptamine): synthesis, structure, and serotonergic binding affinity. ACS Omega 5:16940–16943
Chhabra R, Kremzner ME, Kiliany BJ (2005) FDA policy on unapproved drug products: past, present, and future. Ann Pharmacother 39:1260–1264. https://doi.org/10.1345/aph.1E569
Chi T, Gold JA (2020) A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci 411:116715
Christiansen AL, Rasmussen KE, Hoiland K (1984) Detection of psilocybin and psilocin in Norwegian species of Pluteus and Conocybe. Planta Med 50:341–343. https://doi.org/10.1055/s-2007-969726
COMPASS Pathways (2018) COMPASS pathways receives FDA breakthrough therapy designation for psilocybin therapy for treatment-resistant depression. In: PR Newswire. https://compasspathways.com/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/. Accessed 28 Sep 2020
Dalefield R (2017) Mycotoxins and Mushrooms. Vet Toxicol Aust New Zeal, pp 373–419
Dinis-Oliveira RJ (2017) Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev 49:84–91
Djamshidian A, Bernschneider-Reif S, Poewe W, Lees AJ (2016) Banisteriopsis caapi, a forgotten potential therapy for Parkinson’s Disease? Mov Disord Clin Pract 3:19–26
Dörner S, Rogge K, Fricke J, Schäfer T, Wurlitzer JM, Gressler M, Pham DN, Manke DR, Chadeayne AR, Hoffmeister D (2022) Genetic survey of Psilocybe natural products. Chem Bio Chem 23:e2022002. https://doi.org/10.1002/cbic.202200249
Drug Enforcement Administration (1995) LSD in the United States. US Dept of Justice. http://www.druglibrary.org/schaffer/dea/pubs/lsd/intro.htm
Erritzoe D, Roseman L, Nour MM et al (2018) Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand 138:368–378. https://doi.org/10.1111/acps.12904
Franklin N, Strecker M (2008) Rock Art Studies—News of the World Volume 3. Oxbow Books, Summertown, Oxford
Fricke J, Blei F, Hoffmeister D (2017) Enzymatic synthesis of psilocybin. Angew Chemie Int Ed 56:12352–12355. https://doi.org/10.1002/anie.201705489
Fricke J, Sherwood A, Kargbo R et al (2019a) Enzymatic route toward 6-methylated baeocystin and psilocybin. Chem Bio Chem. https://doi.org/10.1002/cbic.201900358
Fricke J, Lenz C, Wick J et al (2019b) Production options for psilocybin: making of the magic. Chem A Eur J 25:897–903. https://doi.org/10.1002/chem.201802758
Froese T, Guzmán G, Guzmán-Dávalos L (2016) On the origin of the genus Psilocybe and its potential ritual use in ancient Africa and Europe. Econ Bot 70:103–114. https://doi.org/10.1007/s12231-016-9342-2
Garcia-Romeu A, Griffiths RR, Johnson MW (2014) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 7:157–164. https://doi.org/10.2174/1874473708666150107121331
Gartz J (1989) Analysis of aeruginascin in fruit bodies of the mushroom Inocybe aeruginascens. Internat J Crude Drug Res 27:141–144
Gartz J, Moller GK (1989) Analysis and cultivation of fruit bodies and mycelia of Psilocybe bohemica. Biochem Und Physiol Der Pflanz 184:337–341. https://doi.org/10.1016/s0015-3796(89)80023-x
Geiger HA, Wurst MG, Daniels RN (2018) DARK classics in chemical neuroscience: psilocybin. ACS Chem Neurosci 9:2438–2447. https://doi.org/10.1021/acschemneuro.8b00186
Gerber K, Flores I, Ruiz A et al (2021) Ethical concerns about psilocybin intellectual property. ACS Pharmacol Tranl Sci 4:573–577
Glennon RA (2006) Strategies for the development of selective serotonergic agents. In: Roth BL (ed) The serotonin receptors. Humana Press, Totowa
Glennon RA, Peroutka SJ, Dukat M (1991) Binding characteristics of a quaternary amine analog of serotonin: 5-HTQ. In: Fozard JR, Saxena PR (eds) Serotonin: molecular biology, receptors and functional effects. Birkhauser Verlag, Basel
Gotvaldová K, Háikova K, Borovička J, Jurok R, Cihlářová P, Kuchař M (2020) Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis. Drug Test Anal 13:439–446
Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187:268–283. https://doi.org/10.1007/s00213-006-0457-5
Griffiths RR, Richards WA, Johnson MW et al (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22:621–632. https://doi.org/10.1177/0269881108094300
Grob CS, Danforth AL, Chopra GS et al (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116
Guzmán G (1983) The genus Psilocybe. A systematic revision of the known species including the history, distribution and chemistry of the hallucinogenic species. Beihefte Zur Nov Hedwigia 74:1–439
Guzmán G (2008) Hallucinogenic mushrooms in Mexico: an overview. Econ Bot 62:404–412
Guzmán G (2009) The hallucinogenic mushrooms: diversity, traditions, use and abuse with special reference to the genus Psilocybe. In: Misra J, Deshmukh S (eds) Fungi from different environments. Taylor & Francis, New York, pp 256–276
Guzmán G (2015) New studies on hallucinogenic mushrooms: History, diversity, and applications in psychiatry. Int J Med Mushrooms 17:1019–1029. https://doi.org/10.1615/IntJMedMushrooms.v17.i11.10
Guzmán G, Allen JW, Gartz J (1998) A worldwide geographical distribution of the Neurotropic fungi, an analysis and discussion. Ann Mus Civ Rovereto 14:189–280
Guzmán G, Nixon SC, Ramírez-Guillén F, Cortés-Pérez A (2014) Psilocybe s. str. (Agaricales, Strophariaceae) in Africa with description of a new species from the Congo. Sydowia 66:43–53. https://doi.org/10.12905/0380.sydowia66(1)2014-0043
Hanks JB, González-Maeso J (2013) Animal models of serotonergic psychedelics. ACS Chem Neurosci 4:33–42
Hanks JB, González-Maeso J (2016) Hallucinogens: circuits, behavior, and translational models. In: Neuropathology of drug addictions and substance misuse. Academic Press, pp 813–820
Harris D (2022) Anticipating legalization: making psilcybin accessible. Cannabis Sci Techn 5:15–18
Hartman S (2018) Psilocybin Could Be Legal for Therapy by 2021. Roll. Stone 1–1
Hasler F, Grimberg U, Benz MA (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172:145–156
Heim R (1956) Les champignons divinatoires utilisés dans les rites des indiens mazatèques au cours de leur premier voyage au Mexique en 1953, par M. V. Wasson et M. R. G. Wasson. C R Seances Acad Sci 242:965–968
Heim R (1958) Diagnose latine du Psilocybe Wassonii Heim, espèce hallucinogène des Aztèques. Rev Mycol (paris) 23:119–120
Heim R, Hofmann A (1958) Les Champignons Hallucinogènes Du Mexique. Ed. Museum National d’Histoire Naturelle. Paris
Helvenston PA, Bahn PG (2003) Testing the “three stages of trance” model. Cambridge Archaeol J 13:213–224. https://doi.org/10.1017/S0959774303000131
Herraiz T, Chaparro C (2006) Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee. Life Sci 78:795–802
Hofmann A (1958a) Elucidation of the structure and the synthesis of psilocybin. Experientia 14:397–399
Hofmann A (1958b) Chemical aspects of psilocybin, the psychotropic principle from the Mexican fungus. In: Psilocybe mex heim pap present first internat meet neuro-psycho-pharmacology, Rome
Hofmann AR (1959) Psychotomimetic drugs; chemical and pharmacological aspects. Acta Physiol Pharmacol Neerl 8:240–258
Hofmann A, Ruck CAP (2004) Entheogens (Psychedelic Drugs) and Shamanism. Shamanism an Encycl World Beliefs, Pract Cult 1:111–117
Hofmann A, Heim R, Brack A, Kobel H (1958) Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim. Experientia 14:107–109. https://doi.org/10.1007/BF02159243
Hofmann A, Heim R, Brack A et al (1959) Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen. Helv Chim Acta 42:1557–1572. https://doi.org/10.1002/hlca.19590420518
Horita A, Weber LJ (1962) Dephosphorylation of psilocybin in the intact mouse. Toxicol Appl Pharmacol 4:730–737. https://doi.org/10.1016/0041-008X(62)90102-3
Igboeli E, Ajaero C, Anazonwu N, Onuh JC (2021) Geographical variations and determinants of depression status in urban South Africa. J Public Health. https://doi.org/10.1007/s10389-021-01510-4
Jensen N, Gartz J, Laatsch H (2006) Aeruginascin, a trimethylammonium analogue of psilocybin from the hallucinogenic mushroom Inocybe aeruginascens. Planta Med 72:665–666
Johnson MW, Richards WA, Griffiths RR (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603–620
Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology 142:143–166
Jungaberle H, Thal S, Zeuch A et al (2018) Positive psychology in the investigation of psychedelics and entactogens: a critical review. Neuropharmacology 142:179–199
Kargbo RB (2020) Psilocybin therapeutic research: the present and future paradigm. ACS Med Chem Lett 11:399–402
Kargbo RB, Sherwood A, Walker A, Cozzi NV, Dagger RE, Sable J, O’Hern K, Kaylo K, Patterson T, Tarpley G, Meisenheimer P (2020) Direct phosphorilazion of psilocybin enablesoptimized cGMP kilogram scale manufacture of psilocybin. ASC Omega 5:16959–16966
Kenna G, Roder-Hanna N, Leggio L (2012) Pharmacogenomics and personalized medicine association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy. Pharmgenomics Pers Med 5–19
Knopf A (2021) Psilocybin: next to treat depression, OCD and nicotine addiction. Alcoholism Drug Abuse Weekly 33:3–5
Krebs TS, Johansen PØ (2013) Psychedelics and mental health: a population study. PLoS ONE. https://doi.org/10.1371/journal.pone.0063972
Lassen JF, Ravn HB, Lassen SF (1990) Hallucinogene Psilocybinholdige Svampe. Dansk Vildvoksende Rusgift Ugeskr Laeger 152:314–317
Lebedev AV, Lövdén M, Rosenthal G et al (2015) Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp 36:3137–3153. https://doi.org/10.1002/hbm.22833
Lenz C, Wick J, Hoffmeister D (2017) Identification of ω-N-Methyl-4-hydroxytryptamine (Norpsilocin) as a Psilocybe Natural Product. J Nat Prod 80:2835–2838. https://doi.org/10.1021/acs.jnatprod.7b00407
Lenz C, Wick J, Braga D, Garcia-Altares M, Lackner G, Hertweck C, Gressler M, Hoffmeister D (2020) Injury-triggered blueing reactions of Psilocybe “magic” mushrooms. Angew Chem 132:1466–1470
Leung AY, Paul AG (1967) Baeocystin, a mono-methyl analog of psilocybin from Psilocybe baeocystis saprophytic culture. J Pharm Sci 56:146
Leung AY, Paul AG (1968) Baeocystin and norbaeocystin: new analogs of psilocybin from Psilocybe baeocystis. J Pharm Sci 57:1667–1671. https://doi.org/10.1002/JPS.2600571007
Lewis-Williams D, Challis S (2012) Deciphering ancient minds: the mystery of San Bushmen rock art. Choice Rev Online 49:49-2759–49-2759. https://doi.org/10.5860/choice.49-2759
Li N, Hu Y, Chen W, Zhang B (2022) Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. J Affective Disorders 296:26–34
Lin SH, Lee LT, Yang YK (2014) Serotonin and mental disorders: a concise review on molecular neuroimaging evidence. Clin Psychopharmacol Neurosci 12:196–202. https://doi.org/10.9758/cpn.2014.12.3.196
Lindenblatt H, Kramer E, Holzmann-Erens P (1998) Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction. J Chromatogr B Biomed Sci Appl 709:255–263
Liverpool J, Alexander R, Johnson M et al (2004) Western medicine and traditional healers: partners in the fight against HIV/AIDS. J Natl Med Assoc 96:822–825. https://doi.org/10.17615/q8k4-z113
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L (2021) The therapeutic potential of psilocybin. Molecules 26:2948
Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D (2019) Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44:1328–1334
Mamedov NA, Pasdaran A, Mamadalieva NZ (2018) Pharmacological Studies of Syrian Rue (Peganum harmala L., Zygophyllaceae). Int J Sec Metabolite 5:1–6
Mann J (2013) The serotonergic system in mood disorders and suicidal behaviour. Philos Trans R Soc B Biol Sci 368:20120537
Matsushima Y, Eguchi F, Kikukawa T, Matsuda T (2009) Historical overview of psychoactive mushrooms. Inflamm Regen 29:47–58. https://doi.org/10.2492/inflammregen.29.47
Mayett Y, Martínez-Carrera D, Sobal M, Morales P, Bonilla M (2012) Mushroom prices and their effect on consumption: the case of Mexico. Micología Aplicada International 24:11–26
McKernan K, Kane L, Helbert Y, Zhang L, Houde N, McLaughlin S (2021) A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production. F1000Research 10:961
Metzner R, Darling D (2005) Sacred muschroom of visions: teonanácatl: a sourcebook on the psilocybin mushroom. Rochester, Vermont
Milne N, Thomsen P, Knudsen NM, Rubaszka P, Kristensen M, Borodina I (2020) Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives. Metab Eng 60:25–36
Mithoefer MC, Grob CS, Brewerton TD (2016) Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry 3:481–488
Morales D, Shetty SA, López-Plaza B, Gómez-Candela C, Smidt H, Marín FR, Soler-Rivas C (2021) Modulation of human intestinal microbiota in a clinical trial by consumption of a β-D-glucan-enriched extract obtained from Lentinula edodes. Eur J Nutr 60:3249–3265. https://doi.org/10.1007/s00394-021-02504-4
Moreno FA, Wiegand CB, Taitano EK, Delgado PL (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 67:1735–1740. https://doi.org/10.4088/JCP.v67n1110
Musshoff F, Madea B, Beike J (2000) Hallucinogenic mushrooms on the German market—simple instructions for examination and identification. Forensic Sci Int 113:389–395
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181
Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264–355. https://doi.org/10.1124/pr.115.011478
Nichols DE (2020) Psilocybin: from ancient magic to modern medicine. J Antibiot 73:679–686
Nichols DE, Frescas S (1999) Improvements to the synthesis of psilocybin and a facile method for preparing the O-Acetyl prodrug of psilocin. Synthesis 935–938
Nielen RJ, Van der Heijden FMMA, Tuinier S, Verhoeven WMA (2004) Khat and mushrooms associated with psychosis. World J Biol Psychiatry 5:49–53
Osmond H (1957) A review of the clinical effects of psychotomimetic agents. Ann NY Acad Sci 66:418–434. https://doi.org/10.1111/j.1749-6632.1957.tb40738.x
Oss OT, Oeric ON (1991) Psilocybin: magic mushroom grower’s guide. Quick American Pub, San Francisco, California, pp 1–81
Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol 7:357–364. https://doi.org/10.1080/1355621021000005937
Phelps J, Shah RN, Lieberman JA (2022) The rapid rise in investment in psychedelics—cart before the horse. JAMA Psychiat 79:189–190
Poindexter EH, Carpenter RD (1962) The isolation of harmane and norharmane from tobacco and cigarette smoke. Phytochemistry 1:215–221
Puschner B (2018) Mushroom toxins. Veterinary toxicology: basic and clinical principles, 3rd edn. Academic Press, Cambridge, pp 955–966
Rajniak J, Giehl RFH, Chang E, Murgia I, von Wirén N, Sattely ES (2018) Biosynthesis of redox-active metabolites in response to iron deficiency in plants. Nat Chem Biol 14:442–450. https://doi.org/10.1038/s41589-018-0019-2
Rautio J, Kumpulainen H, Heimbach T et al (2008) Prodrugs: design and clinical applications. Nat Rev Drug Discov 7:255–270. https://doi.org/10.1038/NRD2468
Ray TS (2010) Psychedelics and the human receptorome. PLoS ONE 5:1
Redhead SA, Moncalvo J-M, Vilgalys R et al (2007) Proposal to conserve the name Psilocybe (Basidiomycota) with a conserved type. Int Assoc Plant Taxon 56:255–257. https://doi.org/10.2307/25065762
Reiff CM, Richman EE, Nemeroff CB et al (2020) Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry 177:391–410
Reko BP (1919) De los nombres botanicos Aztecas. H. Beyer, Mexico, D.F.
Reko B (1945) Mitobotánica zapoteca. Private Publishing, Tacubaya, D. F., General León
Repke DB, Leslie DT (1977) Baeocystin in Psilocybe semilanceata. J Pharm Sci 66:113–114. https://doi.org/10.1002/jps.2600660130
Repke DB, Leslie DT, Guzmán G (1977) Baeocystin in Psilocybe, Conocybe and Paraeolus. Lloydia 40:566–578
Reynolds HT, Vijayakumar V, Gluck-Thaler E, Korotkin HB, Matheny PB, Slot JC (2018) Horizontal gene cluster transfer increased hallucinogenic mushroom diversity. Evol Lett 2:88–101
Roberts C, Ossborne-Miller L, Cole J et al (2020) Perceived harm, motivations for use and subjective experiences of recreational psychedelic ‘magic’ mushroom use. J Psychopharmacol 3:999–1007
Rommelspacher H, Barbey M, Strauss S, Greiner B, Fahndrich E, Bloom F, Barchas J, Sandler M, Usdin E (1982) Beta-carbolines and tetrahydroisoquinolines. New York
Ross S, Bossis A, Guss J et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30:1165–1180. https://doi.org/10.1177/0269881116675512
Ruck CAP, Bigwood J, Staples D et al (1979) Entheogens. J Psychoactive Drugs 11:145–146. https://doi.org/10.1080/02791072.1979.10472098
Rucker JJH (2015) Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential. BMJ 350:1–2. https://doi.org/10.1136/bmj.h2902
Rucker JJH, Jelen LA, Flynn S et al (2016) Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol 30:1220–1229
Sahagun F (1593) Historia de las cosas de la Nueva España. Pedro Robredo Publishing, Mexico City
Samorini G (1992) The oldest representations of hallucinogenic mushrooms in the world (Sahara Desert, 9000–7000 BP). Integration 2:69–78
Samorini G (2001) new data from the ethnomycology of psychoactive mushrooms. Int J Med Mushrooms 3:1. https://doi.org/10.1615/intjmedmushr.v3.i2-3.180
Schultes RE (1939) Plantae mexicanae II: the identification of teonanacatl, a narcotic basidiomycete of the aztecs. Bot Mus Lealf Harv Univ 7:37–56. https://doi.org/10.5962/p.295127
Schultes RE (1940) Teonanacatl: the narcotic mushroom of the aztecs. Am Anthropol 42:429–443. https://doi.org/10.1525/aa.1940.42.3.02a00040
Sherwood AM, Halberstadt AL, Klein AK, Mccorvy JD, Kaylo KW, Kargbo RB, Meisenheimer P (2020a) Synthesis and biological evaluation of tryptamines found in hallucinogenic mushrooms: norbaeocystin, baeocystin, norpsilocin, and aeruginascin. J Nat Products 83:461–467
Sherwood AM, Kargbo RB, Kaylo KW, Cozzi NV, Meisenheimer P, Kaduk J (2020b) Psilocybin: crystal structure solutions enable phase analysis of prior art and reccently atented examples. Structural Chem C78:36–55
Shirota O, Hakamata W, Goda Y (2003) Concise large-scale synthesis of psilocin and psilocybin, prinicipal chemical constituents of “magic mushroom.” J Nat Prod 83:885–887
Singer R, Smith AH (1958) Mycological Investigations on Teonanacatl, the Mexican Hallucinogenic Mushroom. Part II. A Taxonomic Monograph of Psilocybe, Section Caerulescentes. Mycologia 50:262. https://doi.org/10.2307/3756197
Smith L-A, Ryan J, Evenden R (2017) “It’s like shrooms times a million, plus aliens”: an interpretative phenomenological analysis of experiential accounts from ayahuasca users. In: 19th Annual Transpersonal Psycology Section Conferences, Cober Hill, Scarborough, 18020 September 2015
Snook CP (2016) Indole hallucinogens. Critical care toxicology. Springer International Publishing, Cham, pp 1–22
Spring MG, Ostrow RD, Hallock RM (2016) A profile of those who use hallucinogenic mushrooms. In: Neuropathology of drug addictions and substance misuse, pp 794–800
Stamets P (1999) Psilocybin mushrooms of the world. Ten Speed Press, Berkeley California
Stebelska K (2013) Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities. Ther Drug Monit 35:420–442. https://doi.org/10.1097/FTD.0B013E31828741A5
Stijve T (1995) Worldwide occurence of psychoactive mushrooms—an update. Czech Mycol 48:11–19
Strauss D, Ghosh S, Murray Z, Gryzenhout M (2022) An overview on the taxonomy, phylogenetics and ecology of the psychedelic genera Psilocybe, Panaeolus, Pluteus and Gymnopilus. Front for Global Change 5:813998. https://doi.org/10.3389/ffgc.2022.813998
Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434–1452. https://doi.org/10.1177/0269881110382466
Studerus E, Gamma A, Kometer M, Vollenweider FX (2012) Prediction of psilocybin response in healthy volunteers. PLoS ONE 7:e30800. https://doi.org/10.1371/journal.pone.0030800
Thukral SK, Chawla P, Sharma A, Chawla V (2020) Prodrug approaches for natural products. In: Shah K, Durgesh C, Chauhan N, Mishra P (eds) Recent advancements in prodrugs. CRC Press, Boca Raton, pp 11–27
Tibuhwa DD (2018) Edible and medicinal mushrooms sold at traditional markets in Tanzania. Res J for 12:1–14. https://doi.org/10.3923/rjf.2018.1.14
Tullis P (2021) How ecstasy and psilocybin are shaking up psychiatry. Nature 589:506–510
Tylš F, Páleníček T, Horáček J (2014) Psilocybin—summary of knowledge and new perspectives. Eur Neuropsychopharmacol 24:342–356. https://doi.org/10.1016/j.euroneuro.2013.12.006
Tylš F, Palenicek T, Horacek J (2016a) Neurobiology of the effects of psilocybin in relation to its potential therapeutic targets. In: Neuropathology of drug addictions and substance misuse, pp 782–793
Tylš F, Páleníček T, Kadeřábek L et al (2016b) Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behav Pharmacol 27:309–320. https://doi.org/10.1097/FBP.0000000000000198
Van Amsterdam J, Opperhuizen A, van den Brink W (2011) Harmful potential of magic mushroom use: a review. Regul Toxicol Pharmacol 59:423–429. https://doi.org/10.1016/j.yrtph.2011.01.006
Van Amsterdam J, Van den Brink W (2022) The therapeutic potential of psilocybin: a systematic review. Expert Opin Drug Saf. https://doi.org/10.1080/14740338.2022.2047929
Van Court RC, Wiseman MS, Meyer KW, Ballhorn DJ, Amses K, Slot JC, Dentinger BTM, Garibay-Orijel R, Uehling JK (2022) Diversity, biology, and history of psilocybin-containing fungi: suggestions for research and technological development. Fung Biol 126:308–319
Venturella G, Ferraro V, Cirlincione F, Gargano ML (2021) Medicinal mushrooms: bioactive compounds, use, and clinical trials. Int J Mol Sci 22:634. https://doi.org/10.3390/ijms22020634
Vollenweider FX (2001) Brain mechanisms of hallucinogens and entactogens. Dialogues Clin Neurosci 3:265–279
Vollenweider FX, Leenders KL, Scharfetter C et al (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacol 16:357–372. https://doi.org/10.1016/S0893-133X(96)00246-1
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A et al (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9:3897–3902
Wall MB, Lam C, Ertl N, Kaelen M, Roseman L, Nutt DJ, Carhart-Harris RL (2022) Increased low-frequency brain responses to music after psilocybin therapy for depression. bioRxiv 2022.02.13.480302. https://doi.org/10.1101/2022.02.13.480302
Wang G, Kell DB, Borodina I (2021) Harnessing the yeast Saccharomyces cerevisiae for the production of fungal secondary metabolites. Essays Biochem 65:277–291
Wasson G (1957) Seeking the magic mushroom. Life 42:100–120
Yang ML, Kuo PC, Hwang TL, Wu TS (2011) Anti-inflammatory principles from Cordyceps sinensis. J Nat Products 74:1996–2000
Yockey A, King K (2021) Use of psilocybin (“mushrooms”) among US adults: 2015–2018. J Psychedelic Stud 5:17–21. https://doi.org/10.1556/2054.2020.00159
Zheng W, Wang SZ, Barnes LF, Guan YB, Louis ED (2000) Determination of harmane and harmine in human blood using reversed-phased high-performance liquid chromatography and fluorescence detection. Analytical Biochem 279:125–129
Funding
This work did not received any funding.
Author information
Authors and Affiliations
Contributions
DS: literature search and writing; SG, ZM, MG: editing and supervision.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Strauss, D., Ghosh, S., Murray, Z. et al. Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields. 3 Biotech 12, 339 (2022). https://doi.org/10.1007/s13205-022-03355-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-022-03355-4